Video

Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung Cancer

Nasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.

Nasser H. Hanna, MD, professor of medicine, Indiana University, discusses challenges in consolation immunotherapy for patients with lung cancer.

The biggest challenge is when patients are given consolidation immunotherapy is typically at the same time patients would naturally get radiation pneumonitis, explains Hanna. Symptoms can include inflammation of the lungs, cough, fever, and shortness of breath. Physicians must decide whether the symptoms are related to radiation or immunotherapy because the management is different, says Hanna.

Immune-related pneumonitis can be very complicated and usually requires a pulmonary and infectious disease consult as well as prolonged steroids, according to Hanna. Atypical infections can occur—including viral, fungal, and bacterial infections—and some patients get bronchiolitis obliterans with organizing pneumonia. A question Hanna has for this patient population is whether patients who have low-grade pneumonitis can be rechallenged with consolidation immunotherapy.

<<< View more from the 2019 New York Lung Cancers Symposium

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School